PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Cinnarizine→

Cinnarizine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
298-57-7
Molecular formula
C26H28N2
Molecular weight
368.5139 g/mol
Drug class
Piperazine derivativeantihistamine with calcium-channel-blocking activityantivertigo agent
Mechanism of action
Has antihistaminic activity and inhibits calcium-ion transport across cell membranes. Its calcium-antagonist activity reduces vestibular sensory-cell calcium influx; it also has central vestibular-sedative and antiemetic effects.
Indications / reported uses
  • Control of vestibular disorders such as vertigo, tinnitus, nausea and vomiting associated with Ménière’s disease or other labyrinthine disorders
  • Prevention and control of motion sickness

Sources: UK product SmPC — Cinnarizine 15 mg tablets · NHS medicine information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Cinnarizine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cinnarizine Permitted Daily Exposure (PDE) report (the Cinnarizine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cinnarizine Occupational Exposure Limit (OEL) report (the Cinnarizine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.